 |
 |
|
 |
|
 |
|
|
 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
 Bronchial challenge tests are used in routine diagnostics, in asthma research, clinical trials and in allergen identification. Typically, concentrated stock solutions of provocation agents or specific allergens are diluted on site immediately prior to introduction to a nebuliser. This is often an expensive and inefficient process which can introduce variability to the test protocol between individual tests and between trial sites. The MDE range of Bronchial Challenge Test kits offers a new level of convenience, reliability and reproducibility. MDE manufactures and packs Histamine, Methacholine and Adenosine Monophosphate kits in standard or custom concentration ranges with a 6 to 12 month shelf life depending on the product. All MDE Bronchial Challenge Test kits are manufactured in the EU in GMP accredited aseptic filling units and each delivery is accompanied by a Certificate of Analysis confirming (as a minimum) sterility, product concentration and pyrogenicity. Stability studies on potentially labile products support batch shelf life data. Kits supplied for clinical trial purpose can be labelled according to trial requirements, QP released and transported to trial sites in monitored refrigerated vans. Adenosine Monophosphate Kit: Standard concentration range 0.4, 0.8, 1.5, 3, 6, 12, 25, 50, 100, 200 and 400 mg/ml in standard saline solution. Limited range kits covering part of this range are available as are custom range kits to meet specific requirements. Histamine Kit: Standard concentration range 0.03, 0.06, 0.12, 0.25, 0.5, 1, 2, 4, 8, 16, 32 mg/ml in phosphate buffered saline. Limited range kits covering part of this range are available as are custom range kits to meet specific requirements. Methacholine Kit: Standard concentration range 0.03, 0.06, 0.12, 0.25, 0.5, 1, 2, 4, 8, 16, 32 mg/ml in standard saline. Limited range kits covering part of this range are available as are custom range kits to meet specific requirements.
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
|